lunes, 23 de marzo de 2020

Knowledge of Infectious Disease Specialists Regarding Aspergillosis Complicating Influenza, United States - Volume 26, Number 4—April 2020 - Emerging Infectious Diseases journal - CDC

Knowledge of Infectious Disease Specialists Regarding Aspergillosis Complicating Influenza, United States - Volume 26, Number 4—April 2020 - Emerging Infectious Diseases journal - CDC

Issue Cover for Volume 26, Number 4—April 2020



Volume 26, Number 4—April 2020
Research Letter

Knowledge of Infectious Disease Specialists Regarding Aspergillosis Complicating Influenza, United States

Mitsuru TodaComments to Author , Susan E. Beekmann, Philip M. Polgreen, Tom M. Chiller, Brendan R. Jackson, and Karlyn D. Beer
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Toda, T.M. Chiller, B.R. Jackson, K.D. Beer)University of Iowa, Iowa City, Iowa, USA (S.E. Beekmann, P.M. Polgreen)

Abstract

In an online survey, we found that nearly one fifth of physicians in the United States who responded had seen or heard about a case of invasive pulmonary aspergillosis after severe influenza at their institution. However, <10% routinely used galactomannan testing to test for this fungus in patients with severe influenza.
Invasive pulmonary aspergillosis (IPA) occurs primarily among immunocompromised patients with a history of organ or stem cell transplantation, chemotherapy, or immunosuppressive medications. However, a multicenter retrospective study in the Netherlands and Belgium suggested that patients with severe influenza (i.e., requiring intensive care unit [ICU] admission) are also at risk for IPA (1). In that study, 19% patients with severe influenza showed development of IPA. More than half of these patients were not immunocompromised, and mortality rates were twice as high among ICU patients with IPA compared with those without IPA.
Corticosteroids, which have been associated with higher mortality rates and are used for influenza patients (2), are a known risk factor for IPA and have been associated with IPA in severe influenza (3). However, 44% of patients who showed development of IPA in the study in the Netherlands and Belgium had not received these medications (1). Although case reports exist (4,5), clinicians might not consider IPA as a cause of worsening respiratory function or sepsis because influenza is not considered a classical risk factor for IPA and because of the complexity inherent in diagnosis (6). In the study in the Netherlands and Belgium, IPA cases were diagnosed by galactomannan antigen testing of bronchoalveolar lavage fluid (1). Although galactomannan testing might be useful in the ICU setting (7), it is unclear how often galactomannan testing is performed in the United States.
To clarify clinical practices regarding diagnosis of IPA in patients with severe influenza, the Emerging Infections Network (EIN) surveyed infectious disease specialists in the United States. EIN is a provider-based emerging infections sentinel network supported by the Centers for Disease Control and Prevention and the Infectious Diseases Society of America (8). During May‒June 2018, EIN distributed a 6-question poll to its >1,500 member listserv (https://ein.idsociety.orgExternal Link); 114 responded.
Twenty-nine (26%) respondents were familiar with reports of aspergillosis after severe influenza, and 21 (18%) had seen or heard about >1 case at their institution (Table). Among 108 responding clinicians, 33 (31%) always or very often used lower respiratory tract specimens for diagnostic testing in patients with severe influenza. Only 8 (8%) of 107 clinicians always or very often used lower respiratory specimens and galactomannan testing in patients with severe influenza in the ICU and worsening respiratory function.
Most respondents were unaware of concerns about IPA in severe influenza, suggesting that physicians might not consider it in their differential diagnosis. In addition, most respondents reported infrequent use of galactomannan testing in patients with severe influenza, which might limit ability to detect IPA.
Although our response rate and possible selection bias might limit our ability to draw conclusions, ≈20% of respondents had seen or heard about an IPA case at their institution. IPA in patients with severe influenza might be more common than appreciated based on small numbers of previously published cases in the United States (4,5). Additional research and surveillance are needed to understand the association between IPA and severe influenza and performance of galactomannan testing in patient with severe influenza. Nonetheless, it is essential for clinicians to consider IPA in patients with severe influenza who do not improve with treatment, even in those who are not immunocompromised.
Dr. Toda is an epidemiologist in the Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Her primary research interests are improving disease surveillance and outbreak response for fungal diseases domestically and globally.

Acknowledgments

This study was supported by Cooperative Agreement 1 (U50 CK000477) funded by the Centers for Disease Control and Prevention.
All coauthors contributed to study design. S.E.B. and P.M.P. collected data; M.T. and S.E.B. analyzed data; M.T., B.R.J., and K.D.B. interpreted data; M.T., T.M.C., B.R.J., and K.D.B. wrote the paper; and S.E.B. and P.M.P. supervised the study.

References

  1. Schauwvlieghe  AFADRijnders  BJAPhilips  NVerwijs  RVanderbeke  LVan Tienen  Cet al.Dutch-Belgian Mycosis study groupInvasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med2018;6:78292DOIExternal LinkPubMedExternal Link
  2. Rodrigo  CLeonardi-Bee  JNguyen-Van-Tam  JSLim  WSEffect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis2015;212:18394DOIExternal LinkPubMedExternal Link
  3. Huang  LZhang  NHuang  XXiong  SFeng  YZhang  Yet al. Invasive pulmonary aspergillosis in patients with influenza infection: A retrospective study and review of the literature. Clin Respir J2019;13:20211DOIExternal LinkPubMedExternal Link
  4. Shah  MMHsiao  EIKirsch  CMGohil  ANarasimhan  SStevens  DAInvasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature. Diagn Microbiol Infect Dis2018;91:14752DOIExternal LinkPubMedExternal Link
  5. Crum-Cianflone  NFInvasive aspergillosis associated with severe influenza infections. Open Forum Infect Dis2016;3:ofw171DOIExternal LinkPubMedExternal Link
  6. De Pauw  BWalsh  TJDonnelly  JPStevens  DAEdwards  JECalandra  Tet al.European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative GroupNational Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupRevised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis2008;46:181321DOIExternal LinkPubMedExternal Link
  7. Meersseman  WLagrou  KMaertens  JWilmer  AHermans  GVanderschueren  Set al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med2008;177:2734DOIExternal LinkPubMedExternal Link
  8. Pillai  SKBeekmann  SESantibanez  SPolgreen  PMThe Infectious Diseases Society of America emerging infections network: bridging the gap between clinical infectious diseases and public health. Clin Infect Dis2014;58:9916DOIExternal LinkPubMedExternal Link
Table
Cite This Article

DOI: 10.3201/eid2604.190953
Original Publication Date: 3/11/2020

No hay comentarios:

Publicar un comentario